Xencor, Inc.
Financials
Valuation Metrics
Xencor, Inc.'s Market Cap is $1.44B. At end of 2025 it was $1.14B. Ranked #2229 of 3,111 in US market (top 72%), #886 of 1,445 on NASDAQ (top 61%), #163 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.44B | US#2,229/3,111 Sec#163/269 |
| Revenue | $97M | US#2,791/3,111 Sec#127/269 |
| Net Income | $-172M | US—/3,111 Sec—/269 |
| Total Assets | $737M | US#2,584/3,111 Sec#120/269 |
| Net Assets | $516M | US#2,241/3,111 Sec#112/269 |
| Employees | 260 | US#1,408/3,111 Sec#54/269 |
| Value | ||
| P/B | 2.79x | US#1,655/3,111 Sec#86/269 |
| P/S | 14.77x | US#2,773/3,111 Sec#140/269 |
| FCF Yield | -13.13% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -33.44% | US#2,644/3,111 Sec#136/269 |
| ROA | -23.40% | US#2,824/3,111 Sec#141/269 |
| Op. Margin | -217.93% | US#2,870/3,111 Sec#142/269 |
| Revenue Growth | -86.20% | US#2,930/3,111 Sec#177/269 |
| Financial Health | ||
| Debt Ratio | 42.90% | US#495/3,111 Sec#135/269 |
| Total Debt | $175M | US#2,261/3,111 Sec#100/269 |
| FCF | $-189M | US#2,730/3,111 Sec#214/269 |
| Cash | $14M | US#2,925/3,111 Sec#266/269 |
| Current Ratio | 6.57x | US#362/3,111 Sec#120/269 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,111 Sec—/269 |
| Payout Ratio | 0.00% | US—/3,111 Sec—/269 |
| Performance | ||
| 1Y Return | 143.11% | US#164/3,111 Sec#56/269 |
| 1M Return | 29.33% | US#35/3,111 Sec#4/269 |
| From 52W High | -10.85% | US#735/3,111 Sec#38/269 |
| 1Y MDD | -42.61% | US#2,079/3,111 Sec#155/269 |
| Trading | ||
| Volume | 699,169 shares | US#1,210/3,111 Sec#110/269 |
| Trading Value | $14M | US#1,772/3,111 Sec#123/269 |
| Per Share | ||
| EPS | $-1.24 | US—/3,111 Sec—/269 |
| BPS | $8.84 | US#1,873/3,111 Sec#73/269 |
Company Info
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.